STAAR Surgical Company
STAAR Surgical designs, manufactures, and sells implantable lenses for the eye and the accessory delivery systems used to place them. Its core business centers on Collamer® implantable collamer lenses (ICLs), which are used in refractive eye surgery and sold across the Americas, Europe, the Middle East, Africa, and Asia-Pacific.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenuePhakic implantable lenses used in refractive surgery to correct vision without removing the natural lens.
Devices and tools used by surgeons to deliver ICLs into the eye during procedures.
Customers
Customers are ophthalmic surgeons, refractive surgery centers, and eye-care providers that perform elective vision-correction procedures. The end patients are typically adults seeking alternatives to eyeglasses or contact lenses, especially where ICLs are preferred for high refractive error or when corneal tissue removal is less suitable.
Buy ICLs and delivery systems for elective refractive procedures and value predictable surgical workflow.
Purchase and distribute ICL products in markets served through channel partners.
Use the lenses in vision-correction procedures and rely on surgeon education and support.
End users who choose ICL procedures for visual freedom and reversible lens implantation.
Strategy
STAAR’s strategy is to expand the availability of its full ICL product line in existing markets while entering additional countries where refractive surgery demand can support adoption. It also emphasizes awareness-building, surgeon training, and clinical education to increase procedure adoption and strengthen its position in newer markets.
A wider product footprint increases procedure adoption and deepens penetration in served markets.
ICL adoption depends on surgeon familiarity, procedural confidence, and patient education.
The business relies on recurring procedure volume and distributor/surgeon engagement across regions.
Geography
STAAR sells worldwide, with business concentrated in Asia-Pacific, EMEA, and the Americas. The company specifically cites sales growth in Korea, Japan, China, India, Canada, the U.S., and Latin America distributor markets, showing a geographically diversified refractive-surgery footprint.
Risks
STAAR is exposed to demand concentration in refractive surgery markets, especially China and other APAC countries, where regional swings can materially affect sales. It also faces execution risk around product adoption, distributor performance, regulatory approvals, and the costs and uncertainties tied to the proposed merger process described in the filing.
- China demand volatilityImpact: HighLikelihood: High
A large portion of sales is tied to APAC, and China sales have shown sharp swings in reported periods.
Exposure: APAC revenue and global growth rate
- Merger-related transaction riskImpact: HighLikelihood: High
The filing describes stockholder approval, litigation, and regulatory conditions that may not be satisfied.
Exposure: Corporate transaction process
- Market adoption and surgeon education riskImpact: MediumLikelihood: High
ICL procedures require surgeon familiarity and patient acceptance to expand volume.
Exposure: Newer markets and product penetration
- Distributor/channel execution riskImpact: MediumLikelihood: High
International sales rely partly on distributor markets, which can affect inventory, sell-through, and pricing.
Exposure: EMEA and APAC distributor markets
- Foreign exchange exposureImpact: MediumLikelihood: Medium
Global sales create translation and transaction exposure across multiple currencies.
Exposure: Reported revenue and margins
Accounting
Judgemental itemsNet sales are driven mainly by ICL shipments, and return allowances can change reported revenue timing and net realizations.
Impact: Quarterly revenue comparability
The company recognized severance, consulting, asset impairments, and software write-downs tied to organizational changes.
Impact: Operating expense and asset carrying values
Impairment of leased-property right-of-use assets indicates lease-related judgments can affect balance sheet values.
Impact: Balance sheet and expense recognition
Global operations create translation and transaction impacts that can move reported sales and other income.
Impact: Reported revenue and other income
Similar listed companies
Publicly listed companies with a comparable business focus.
LENSAR, Inc.
LNSR · Surgical & Medical Instruments & Apparatus
Alcon Inc
ALC · Ophthalmic Goods
Alcon Inc is a United States-based ophthalmic goods company focused on eye care products and surgical ophthalmology solutions.
Sight Sciences, Inc.
SGHT · Surgical & Medical Instruments & Apparatus
Innovative Eyewear Inc
LUCYW · Ophthalmic Goods
Innovative Eyewear Inc designs and commercializes smart eyewear that combines prescription or fashion frames with audio, communication, and connected-device functionality.
RxSight, Inc.
RXST · Ophthalmic Goods
GLAUKOS Corp
GKOS · Surgical & Medical Instruments & Apparatus
Glaukos Corp develops and commercializes ophthalmic therapies and devices focused on glaucoma, corneal disorders, and emerging anterior/posterior segment treatments.
Last updated: 24/09/2026